Stocks
Amgen Shares Breakthroughs in Small Cell Lung Cancer Research at WCLC 26
Amgen shared its excitement about the progress being made in small cell lung cancer (SCLC) research at WCLC 26. According to Amgen, innovation in SCLC isn't just a single discovery but rather the result of years of collaboration and scientific exchange.
The company highlighted new data from several studies presented at the conference, showcasing advancements in the field. This year's WCLC marks a significant milestone for targeted therapy in SCLC treatment, as it enters a new therapeutic era.